ASIA PACIFIC BREAST IMPLANTS MARKET ANALYSIS

Market Challenges And Opportunities

• Product Recall by the regulatory authority 

Asia Pacific Breast Implants Market : Restraint

Product Recall by the regulatory authority

The government is taking action to reduce the adverse events associated with the breast implants and breast augmentation surgeries. For instance, in July 2019, according to the data published by the National Center for Biotechnology Information, the U.S. Food and Drug Administration, requested Allergan, a pharmaceutical company to recall its Biocell textured breast implants because they had been linked to Breast Implant Associated Lymphoma (BIA-ALCL), or breast implant-associated anaplastic large cell lymphoma, a rare cancer. The U.S. Food and Drug Administration recommends women with BIA-ALCL to have their implants removed. Furthermore, in August 2022, the U.S. Food and Drug Administration reported that it had received 1,130 reports of BIA-ALCL, and 953 of those reports were related to Allergan implants. Moreover, in September 2022, the U.S. Food and Drug Administration received additional reports of other types of cancer not related to BIA-ALCL found in scar tissue of smooth and textured implants. Thus, product recall by the regulatory authority is the major factor that can hamper the growth of the Asia Pacific breat implants market over the forecast period. The launch of breast implants made with the bioresorbable polymer can reduce the adverse events of Breast Implant Associated Lymphoma (BIA-ALCL).

Asia Pacific Breast Implants Market Cross Sectional Analysis:

In the product type segment, silicone breast implant segment held a dominant position in the China due to the increasing number of research and development activity for the cosmetic surgeries for breast enlargement. For instance, in February 2020, Allergan Plc., pharmaceutical company, initiated a clinical trial study to evaluate the safety of McGhan single lumen gel-filled breast implants in patients in China. In this study, a retrospective chart analysis, analyzes the medical files of patients who underwent breast augmentation or reconstruction using McGhan silicone breast implants between December 24, 2017 and December 31, 2020, and who were enrolled in about 5 hospitals or clinics in China.

Asia Pacific Breast Implants Market Driver

Increasing clinical trial study to evaluate safety and efficacy of the breast implants to drive the Asia Pacific breast implants market over the forecast period

Th major market player are focused on carrying out clinical trials for launching new breast implants in the market. For instance, in June 2022, BellaSeno Pty Ltd, medical technology company, an Australia-based company, initiated a clinical trial for surgical implantation of the PCL breast scaffold with autologous fat grafting. The clinical trial study is estimated to get completed by June, 2026.